JAMA Oncology "Research Letter" titled "Upadacitinib for Immune Checkpoint Inhibitor-Related Dermatitis: A Nonrandomized Clinical Trial" by Chengshui Chen, MD, PhD1; Xinyu Liang, MD1; Zheng Peng, MD1; et al. Published Online: March 5, 2026.
Oral upadacitinib achieved rapid resolution and pruritus relief in severe immune checkpoint inhibitor–related #Dermatitis, with no serious treatment-related adverse events.
ja.ma/3MVSbwT